| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine |
-Methyl Tyrosine versus FDG—Preliminary Study1
1 From the Departments of Nuclear Medicine (T.I., K.K., N.O., S.A., Z.Y., Y.T., K. Tomiyoshi, K.E.) and Diagnostic Radiology (J.A.), Gunma University School of Medicine, 3-39-22 Showa-machi Maebashi, Gunma 371-8511 Japan; and the Departments of Medical Information (H.S.) and Nursing (K. Takeuchi), Gunma Prefectural College of Health Sciences, Japan. Received August 19, 1999; revision requested October 7; final revision received December 28, 2000; accepted January 16, 2001. Address correspondence to T.I. (e-mail: tomioi@med.gunma-u.ac.jp).
PURPOSE: To compare the diagnostic potential of whole-body positron emission tomography (PET) with fluorine 18 
-methyl tyrosine (FMT) with that of whole-body PET with 2-[fluorine 18]fluoro-2-deoxy-D-glucose (FDG).
MATERIALS AND METHODS: Nineteen patients with or suspected of having malignant tumors and five healthy volunteers underwent whole-body PET with FMT and FDG.
RESULTS: In comparison with FDG uptake, FMT uptake was significantly less in the brain, heart, lung, liver, and spine. On a lesion-by-lesion basis, the sensitivity of whole-body FMT PET for depicting malignant tumors was inferior to that of whole-body FDG PET, but this difference was not statistically significant (74% [26 of 35 lesions] vs 91% [32 of 35 lesions], P > .05). The positive predictive value of FMT PET was superior to that of FDG PET (87% [26 of 30 lesions] vs 63% [32 of 51 lesions], P < .001). The difference in uptake between benign and malignant lesions was significant with FMT PET (mean ± SD, 1.64 ± 0.96 vs 0.79 ± 0.23; P < .001) but not with FDG PET (5.02 ± 3.56 vs 4.02 ± 2.90, P > .05).
CONCLUSION: Whole-body FMT PET is clinically useful in the diagnosis of malignant tumors and may be effective in the depiction of primary and metastatic lesions in the cardiac region or in the brain.
Index terms: Fluorine, radioactive • Metabolism • Neoplasms, PET, **.121632, **.12166 • Positron emission tomography (PET), comparative studies, **.12163, **.12166, 10.12173 • Positron emission tomography (PET), technology, **.12163, **.12166, 10.12173
This article has been cited by other articles:
|
|
 |
|
  K. Kaira, N. Oriuchi, Y. Otani, K. Shimizu, S. Tanaka, H. Imai, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, et al. Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic Study Clin. Cancer Res., November 1, 2007; 13(21): 6369 - 6378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kaira, N. Oriuchi, Y. Otani, N. Yanagitani, N. Sunaga, T. Hisada, T. Ishizuka, K. Endo, and M. Mori Diagnostic Usefulness of Fluorine-18-{alpha}-Methyltyrosine Positron Emission Tomography in Combination With 18F-Fluorodeoxyglucose in Sarcoidosis Patients Chest, April 1, 2007; 131(4): 1019 - 1027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Pauleit, G. Stoffels, W. Schaden, K. Hamacher, D. Bauer, L. Tellmann, H. Herzog, S. Broer, H. H. Coenen, and K.-J. Langen PET with O-(2-18F-Fluoroethyl)-L-Tyrosine in Peripheral Tumors: First Clinical Results J. Nucl. Med., March 1, 2005; 46(3): 411 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shikano, K. Kawai, L. G. Flores II, R. Nishii, N. Kubota, N. Ishikawa, and A. Kubodera An Artificial Amino Acid, 4-Iodo-L-meta-Tyrosine: Biodistribution and Excretion via Kidney J. Nucl. Med., April 1, 2003; 44(4): 625 - 631. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| RADIOLOGY | RADIOGRAPHICS | RSNA JOURNALS ONLINE |
